346 related articles for article (PubMed ID: 31805871)
1. Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria.
Jahn B; Sroczynski G; Bundo M; Mühlberger N; Puntscher S; Todorovic J; Rochau U; Oberaigner W; Koffijberg H; Fischer T; Schiller-Fruehwirth I; Öfner D; Renner F; Jonas M; Hackl M; Ferlitsch M; Siebert U;
BMC Gastroenterol; 2019 Dec; 19(1):209. PubMed ID: 31805871
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
4. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
5. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.
Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM
JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness and projected national impact of colorectal cancer screening in France.
Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
[TBL] [Abstract][Full Text] [Related]
7. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
Wong CK; Lam CL; Wan YF; Fong DY
BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
10. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
11. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
[TBL] [Abstract][Full Text] [Related]
12. Long-term benefits and harms of early colorectal cancer screening in German individuals with familial cancer risk.
Sroczynski G; Hallsson LR; Mühlberger N; Jahn B; Rehms R; Hoffmann S; Crispin A; Lindoerfer D; Mansmann U; Siebert U
Int J Cancer; 2024 Feb; 154(3):516-529. PubMed ID: 37795630
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
[TBL] [Abstract][Full Text] [Related]
14. The economic evaluation of screening for colorectal cancer: Case of Iran.
Barouni M; Ghaderi H; Shahmoradi MK
Clin Lab; 2013; 59(5-6):667-74. PubMed ID: 23865368
[TBL] [Abstract][Full Text] [Related]
15. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality.
D'Andrea E; Ahnen DJ; Sussman DA; Najafzadeh M
Cancer Med; 2020 Jan; 9(2):824-836. PubMed ID: 31777197
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of screening for colorectal cancer in the general population.
Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
[TBL] [Abstract][Full Text] [Related]
18. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.
Goede SL; Rabeneck L; van Ballegooijen M; Zauber AG; Paszat LF; Hoch JS; Yong JH; Kroep S; Tinmouth J; Lansdorp-Vogelaar I
PLoS One; 2017; 12(3):e0172864. PubMed ID: 28296927
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
Sonnenberg A; Delcò F; Inadomi JM
Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T
J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
